Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. A 10-Year Follow-up Study of the Natural History of Perianal Crohn's Disease in a Danish Population-Based Inception Cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk Loci

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Inflammatory Bowel Disease and Parkinson's Disease: A Nationwide Swedish Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Changing Infliximab Prescription Patterns in Inflammatory Bowel Disease: A Population-Based Cohort Study, 1999-2014

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Is revision of cutoff values needed when using CD3 immunohistochemical staining in histopathologic diagnosis of lymphocytic colitis?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Treatment of candidemia in a nationwide setting: increased survival with primary echinocandin treatment

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Effects of liraglutide on gallbladder emptying: a randomised, placebo-controlled trial in adults with overweight or obesity

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Mette Julsgaard
  • Christian L Hvas
  • Richard B Gearry
  • Peter R Gibson
  • Jan Fallingborg
  • Miles P Sparrow
  • Bo M Bibby
  • William R Connell
  • Steven J Brown
  • Michael A Kamm
  • Ian C Lawrance
  • Thea Vestergaard
  • Lise Svenningsen
  • Mille Baekdal
  • Heidi Kammerlander
  • Alissa Walsh
  • Trine Boysen
  • Peter Bampton
  • Graham Radford-Smith
  • Jens Kjeldsen
  • Jane M Andrews
  • Kavitha Subramaniam
  • Gregory T Moore
  • Nanna M Jensen
  • Susan J Connor
  • Signe Wildt
  • Benedicte Wilson
  • Kathrine Ellard
  • Lisbet A Christensen
  • Sally J Bell
View graph of relations

BACKGROUND: Active inflammatory bowel disease (IBD) adversely affects pregnancy outcomes. Little is known about the risk of relapse after stopping anti-tumor necrosis factor (anti-TNF) treatment during pregnancy. We assessed the risk of relapse before delivery in women who discontinued anti-TNF treatment before gestational week (GW) 30, predictors of reduced infant birth weight, a marker associated with long-term adverse outcomes, and rates and satisfaction with counseling.

METHODS: Pregnant women with IBD receiving anti-TNF treatment were prospectively invited to participate in an electronic questionnaire carried out in 22 hospitals in Denmark, Australia, and New Zealand from 2011 to 2015. Risk estimates were calculated, and birth weight was investigated using t tests and linear regression.

RESULTS: Of 175 women invited, 153 (87%) responded. In women in remission, the relapse rate did not differ significantly between those who discontinued anti-TNF before GW 30 (1/46, 2%) compared with those who continued treatment (8/74, 11%; relative risk, 0.20; 95% confidence interval [CI], 0.02 to 1.56; P = 0.08). Relapse (P = 0.001) and continuation of anti-TNF therapy after GW 30 (P = 0.007) were independently associated with reduced mean birth weight by 367 g (95% CI, 145 to 589 g; relapse) and 274 g (95% CI, 77 to 471 g; anti-TNF exposure after GW 30). Of 134 (88%) women who received counseling, 116 (87%) were satisfied with the information provided.

CONCLUSIONS: To minimize fetal exposure in women in remission, discontinuation of anti-TNF before GW 30 seems safe. Relapse and continuation of anti-TNF therapy after GW 30 were each independently associated with lower birth weight, although without an increased risk for birth weight <2500 g. Most women received and were satisfied with counseling.

Original languageEnglish
JournalInflammatory Bowel Diseases
ISSN1078-0998
DOIs
Publication statusE-pub ahead of print - 29 May 2019

ID: 57450069